Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, was named one of the top 100 Most Innovative Artificial Intelligence Startups in the world by CB Insights. This is the second year Insilico has earned a place on the AI 100 and the sixth year CB Insights has recognized the most promising private AI companies with its ranking. The winners were selected from over 7,000 global companies on the strength of their groundbreaking AI technologies and likelihood of future success. They span 13 different industries and have collectively raised $12 billion+ from 650 investors across 300+ equity deals.

"Last year's AI 100 companies had a remarkable run, raising more than $6 billion, including 20 mega-rounds worth more than $100 million each," said Brian Lee, SVP of CB Insights' Intelligence Unit. "We're excited to watch the companies on this year's list continue to grow and create products and services that meaningfully impact the world around them."

Founded in 2014, Insilico Medicine is focused on AI-driven drug discovery and has the first AI-discovered and AI-designed therapeutic for idiopathic pulmonary fibrosis (IPF) currently in Phase 1 clinical trials. In addition, Insilico has announced 7 preclinical candidates since 2021 for a number of disease indications including kidney fibrosis, cancer, chronic kidney disease, and inflammatory bowel disease. Most recently, Insilico announced two novel cancer drugs in the synthetic lethality space, a USP1 inhibitor for BRCA mutant cancers and an MAT2A inhibitor for MTAP-deleted cancers.

"Insilico was born at the cusp of the deep learning revolution and CB Insights started tracking the AI industry from the very early days. We were very happy to be in AI100 in 2018. In 2020 we were the top 150 in healthcare. This year, we are very happy to receive this recognition once again from CB Insights, a leading industry analyst," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "This has been another exciting year for Insilico, in which we progressed into human trials with our IPF drug and accelerated a number of other novel therapeutics through our internal pipeline, including two new synthetic lethality cancer drugs, one of the most promising areas of cancer research. We have transformed from AI-first to a clinical-stage AI-powered biotechnology powerhouse."

Insilico's growing portfolio of novel therapeutics are being developed through the strength of its AI drug discovery platform, PHARMA.AI, which includes novel target discovery (PandaOmics), novel small molecule generation (Chemistry42) and clinical trial prediction (InClinico).